Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | REN | P00797 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14903256 | 0.92 | TACR1 (0.45) | CTRB1TACR1CTSCNTMT1REN | |
| SCHEMBL14903396 | 0.92 | TACR1 (0.45) | CTRB1TACR1CTSCNTMT1REN | |
| SCHEMBL6880651 | 0.86 | CTRB1 (0.49) | CTRB1CTSCRENDPP4DPP8 | |
| SCHEMBL6879220 | 0.86 | CTRB1 (0.49) | CTRB1CTSCRENDPP4DPP8 | |
| SCHEMBL6876472 | 0.84 | CTRB1 (0.48) | CTRB1TACR1CTSCRENDPP4 | |
| SCHEMBL6880524 | 0.84 | CTRB1 (0.48) | CTRB1TACR1CTSCRENDPP4 | |
| SCHEMBL6878588 | 0.84 | CTRB1 (0.48) | CTRB1TACR1CTSCRENDPP4 | |
| SCHEMBL6876603 | 0.84 | CTRB1 (0.48) | CTRB1TACR1CTSCRENDPP4 | |
| SCHEMBL14906471 | 0.84 | CTRB1 (0.48) | CTRB1TACR1CTSCRENDPP4 | |
| SCHEMBL14906464 | 0.84 | CTRB1 (0.48) | CTRB1TACR1CTSCRENDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238713-B2 | Cyclic tetrapeptides and therapeutic applications thereof | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2019-03-26 | — | — | US | disclosed |
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | LODZ UNIVERSITY OF TECHNOLOGY (PL) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157204-A1 | CYCLIC TETRAPEPTIDES AND THERAPEUTIC APPLICATIONS THEREOF | PNISR, APLNR, VIP | CTRB1 1251/4885TACR1 81/4885CTSC 419/4885 |
| US-10238713-B2 | Cyclic tetrapeptides and therapeutic applications thereof | PNISR, APLNR, VIP | CTRB1 1251/4885TACR1 81/4885CTSC 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.